ClinicalTrials.gg
Active, not recruitingNCT05726630LIBERIUSUpdated Jun 10, 2026

Clinical Study of Divozilimab in Patients With Systemic Scleroderma

A Phase 3 interventional study of Divozilimab and Placebo in Systemic Scleroderma, sponsored by Biocad. Active, not recruiting at 3 sites in Russia. Open to participants aged 16 Years and older. Per ClinicalTrials.gov, last updated 2026-06-10.

Sponsored by Biocad · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
152
Allocation
Randomized
Ages
16 Years and older
Sex
All
01

Study summary

The study is a randomized, double-blind, placebo-controlled clinical study of the efficacy and safety of divozilimab in patients with systemic scleroderma.The study will enroll adult patients of both sexes diagnosed with active systemic scleroderma according to the ACR/EULAR 2013 criteria with a modified Rodnan skin score (mRSS) of 10 to 20. In patients having signs of ILD, the Forced Vital Capacity (FVC) should be at least 40 % of the due value.

The study will include patients of either sex aged ≥16 years with systemic scleroderma according to the ACR/EULAR 2013 criteria, with a modified Rodnan skin score (mRSS) ≥10 and ≤20 , as well as patients of either sex aged ≥14 and \<16 years with systemic scleroderma according to the PRES/ACR/EULAR 2007 criteria. In patients having signs of ILD, the Forced Vital Capacity (FVC) should be at least 40 % of the due value. Subjects aged ≥18 years will be randomized to divozilimab or placebo group. Subjects aged \<18 years (not less than 16) will receive divozilimab.

02

Conditions studied

  • Systemic Scleroderma

Browse trials for

03

In context

Scleroderma, Systemic

613 studies on the registry are indexed under Scleroderma, Systemic; 221 are open to participants now.

This study's enrollment of 152 is above the median of 37 across 449 interventional studies indexed under Scleroderma, Systemic.

Browse Scleroderma, Systemic studies →

Lead sponsor

Biocad is the lead sponsor of 94 studies on the registry; 12 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
16 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • For subjects aged ≥16 years: a diagnosis of systemic scleroderma according to the ACR/EULAR 2013 criteria; a modified Rodnan skin score (mRSS) ≥10 and ≤20
  • For subjects aged ≥14 and \<16 years: a diagnosis of systemic scleroderma according to the PRES/ACR/EULAR 2007 criteria.
  • FVC ≥ 40 % of the due value.

Exclusion criteria

Exclusion Criteria:

  • Induced scleroderma.
  • Silicone implants/protheses.
  • Digital ulcers with signs of infection or indications for any amputation.
  • Blood biochemistry or hematological abnormalities at screening.
  • /FVC \< 0.7 and FEV1\< 50 % at screening.
  • History of threatment with anti-CD20 monoclonal antibodies.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

FEV1

From a breathing test (spirometry): how much air you can blow out in the first second. Often given as a percentage of what is expected for your age, height and sex.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
152 participants (actual)

Study arms

  • Experimental
    Divozilimab

    Drug: Divozilimab

  • Placebo comparator
    Placebo

    Drug: Placebo

Interventions

  • anti CD20 monoclonal antibody

  • DrugPlacebo

    Placebo

06

What researchers measure

Primary outcomes

  1. Change in the modified Rodnan Skin Score (mRSS) from baseline

    The modified Rodnan Skin Score (mRSS) describes the thickness of skin in 17 anatomic areas rated from 0 to 3, where 3 indicates the most severe thickening.

    Time frame: week 48

Secondary outcomes

  1. Change in Forced Vital Capacity (FVC) from baseline

    FVC (Forced Vital Capacity) desribes pulmonary function. FVC will be assessed using a spirometer.

    Time frame: week 48

07

Study locations

3 sites
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Dec 2022 to primary completion in Oct 2024, 21 months.

Of 17 phase 3 interventional studies under Scleroderma, Systemic, half reached primary completion within 25 months of starting (the median), counting those still running; a quarter within 21 and three quarters within 54. This study's 21 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 3, 2023
First posted
Feb 14, 2023
StartActual
Dec 26, 2022
Primary completionActual
Oct 1, 2024
CompletionEst.
Feb 1, 2027
Last update
Jun 10, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 10, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT05726630
Lead sponsor
Biocad
Responsible party
Sponsor
First posted
Feb 14, 2023
Start date
Dec 26, 2022
Primary completion
Oct 1, 2024
Completion
Feb 1, 2027 (estimated)
Last update
Jun 10, 2026

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Jun 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Divozilimab

Start the discussion